Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505
Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505 million and was ranked 37th on thepublication's list.
The majority of Omnipaque's revenue derived from U.S. sales,which were pegged at $480 million in 1993 -- up 1% from the $475million in sales recorded the year before.
The next best selling imaging agent on the list was Bristol-MyersSquibb's Isovue. The x-ray imaging product recorded worldwidesales of $310 million in 1993, down 7.4% from the $335 millionregistered in 1992. Isovue had U.S. sales of $305 million in 1993and $320 million the year before.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.